Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer.

Ardeshir-Larijani F, Bhateja P, Lipka MB, Sharma N, Fu P, Dowlati A.

Clin Lung Cancer. 2018 Mar 16. pii: S1525-7304(18)30047-0. doi: 10.1016/j.cllc.2018.03.005. [Epub ahead of print]

PMID:
29627316
2.

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM.

N Engl J Med. 2018 Feb 22;378(8):731-739. doi: 10.1056/NEJMoa1714448.

PMID:
29466156
3.

The FACT inhibitor CBL0137 synergizes with cisplatin in small cell lung cancer by increasing NOTCH1 expression and targeting tumor-initiating cells.

De S, Lindner DJ, Coleman C, Wildey G, Dowlati A, Stark GR.

Cancer Res. 2018 Feb 13. pii: canres.1920.2017. doi: 10.1158/0008-5472.CAN-17-1920. [Epub ahead of print]

PMID:
29440145
4.

Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies.

Caimi PF, Cooper BW, William BM, Dowlati A, Barr PM, Fu P, Pink J, Xu Y, Lazarus HM, de Lima M, Gerson SL.

Oncotarget. 2017 Aug 9;8(45):79864-79875. doi: 10.18632/oncotarget.20094. eCollection 2017 Oct 3.

5.

Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer.

McColl K, Wildey G, Sakre N, Lipka MB, Behtaj M, Kresak A, Chen Y, Yang M, Velcheti V, Fu P, Dowlati A.

Oncotarget. 2017 Aug 28;8(43):73745-73756. doi: 10.18632/oncotarget.20572. eCollection 2017 Sep 26.

6.

Relationship between phase I study duration and symptom burden.

Treasure M, Daly B, Fu P, Kerpedjieva S, Dowlati A, Meropol NJ.

Support Care Cancer. 2018 Mar;26(3):731-737. doi: 10.1007/s00520-017-3879-1. Epub 2017 Oct 5.

PMID:
28980072
7.

Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer.

Bhateja P, Dowlati A, Sharma N.

Invest New Drugs. 2017 Oct 2. doi: 10.1007/s10637-017-0515-3. [Epub ahead of print]

PMID:
28971268
8.

Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.

Gerber DE, Swanson P, Lopez-Chavez A, Wong L, Dowlati A, Pennell NA, Cronier DM, Qin A, Ilaria R Jr, Cosaert J, Shahir A, Baggstrom MQ.

Lung Cancer. 2017 Sep;111:108-115. doi: 10.1016/j.lungcan.2017.07.009. Epub 2017 Jul 18.

PMID:
28838379
9.

Prognostic potential of neutrophil-to-lymphocyte ratio and lymphocyte nadir in stage III non-small-cell lung cancer.

Kang KH, Efird JT, Sharma N, Yang M, Dowlati A, Linden P, Machtay M, Biswas T.

Future Oncol. 2017 Jul;13(16):1405-1414. doi: 10.2217/fon-2017-0045. Epub 2017 Jul 7.

PMID:
28685599
10.

[How I explore…. HLA class II by ultrastructure in toxic epidermal necrolysis].

Piérard GE, Dowlati A, Piérard-Franchimont C, Paquet P, Delvenne P.

Rev Med Liege. 2016 Jun;71(6):298-301. Review. French.

11.

Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial.

Tacastacas JD, Chan DV, Carlson S, Gerson SL, Dowlati A, Fu P, Lu K, Groft S, Rosenjack J, Honda K, McCormick TS, Cooper KD.

JAMA Dermatol. 2017 May 1;153(5):413-420. doi: 10.1001/jamadermatol.2016.5793.

12.

Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis.

Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, Ni A, Khodos I, de Stanchina E, Nguyen T, Sage J, Campbell JE, Ribich S, Rekhtman N, Dowlati A, Massion PP, Rudin CM, Poirier JT.

Cancer Cell. 2017 Feb 13;31(2):286-299. doi: 10.1016/j.ccell.2017.01.006.

13.

A Pharmacokinetic and Safety Study of Trebananib, an Fc-Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction.

Wu B, Lewis LD, Harvey RD, Rasmussen E, Gamelin E, Sun YN, Friberg G, Koyner JL, Dowlati A, Maitland ML.

Clin Pharmacol Ther. 2017 Aug;102(2):313-320. doi: 10.1002/cpt.617. Epub 2017 Jun 9.

PMID:
28074547
14.

Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).

Augert A, Zhang Q, Bates B, Cui M, Wang X, Wildey G, Dowlati A, MacPherson D.

J Thorac Oncol. 2017 Apr;12(4):704-713. doi: 10.1016/j.jtho.2016.12.011. Epub 2016 Dec 19.

15.

RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR.

Sakre N, Wildey G, Behtaj M, Kresak A, Yang M, Fu P, Dowlati A.

Oncotarget. 2017 Jan 24;8(4):5992-6002. doi: 10.18632/oncotarget.13362.

16.

Radiosensitization of non-small-cell lung cancer cells and xenografts by the interactive effects of pemetrexed and methoxyamine.

Oleinick NL, Biswas T, Patel R, Tao M, Patel R, Weeks L, Sharma N, Dowlati A, Gerson SL, Fu P, Zhang J, Machtay M.

Radiother Oncol. 2016 Nov;121(2):335-341. doi: 10.1016/j.radonc.2016.10.007. Epub 2016 Nov 9.

PMID:
27838149
17.

Evaluating the role of phase I expansion cohorts in oncologic drug development.

Norris RE, Behtaj M, Fu P, Dowlati A.

Invest New Drugs. 2017 Feb;35(1):108-114. doi: 10.1007/s10637-016-0394-z. Epub 2016 Oct 7. Review.

PMID:
27718038
18.

A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer.

Chiappori AA, Otterson GA, Dowlati A, Traynor AM, Horn L, Owonikoko TK, Ross HJ, Hann CL, Abu Hejleh T, Nieva J, Zhao X, Schell M, Sullivan DM.

Oncologist. 2016 Oct;21(10):1163-1164. Epub 2016 Sep 30.

19.

Genomic alterations in small cell lung cancer and their clinical relevance.

Wildey G, Dowlati A.

Transl Lung Cancer Res. 2016 Aug;5(4):450-1. doi: 10.21037/tlcr.2016.07.05. No abstract available.

20.

Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer.

Fu P, Pennell NA, Sharma N, Yi Q, Dowlati A.

Rev Recent Clin Trials. 2017;12(1):51-58. doi: 10.2174/1574887111666160916130423.

PMID:
27633965
21.

Comparison of cisplatin/etoposide versus carboplatin/etoposide concurrent chemoradiation therapy for limited-stage small cell lung cancer (LS-SCLC) in the elderly population (age >65 years) using national SEER-Medicare data.

Kim E, Biswas T, Bakaki P, Dowlati A, Sharma N, Machtay M.

Pract Radiat Oncol. 2016 Sep-Oct;6(5):e163-9. doi: 10.1016/j.prro.2016.01.011. Epub 2016 Jan 28.

PMID:
27142494
22.

A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors.

Dowlati A, Vlahovic G, Natale RB, Rasmussen E, Singh I, Hwang YC, Rossi J, Bass MB, Friberg G, Pickett CA.

Clin Cancer Res. 2016 Sep 15;22(18):4574-84. doi: 10.1158/1078-0432.CCR-15-2145. Epub 2016 Apr 13.

23.

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Bunn PA Jr, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR.

J Thorac Oncol. 2016 Apr;11(4):453-74. doi: 10.1016/j.jtho.2016.01.012. Epub 2016 Jan 30. Review. No abstract available.

24.

Clinical correlation of extensive-stage small-cell lung cancer genomics.

Dowlati A, Lipka MB, McColl K, Dabir S, Behtaj M, Kresak A, Miron A, Yang M, Sharma N, Fu P, Wildey G.

Ann Oncol. 2016 Apr;27(4):642-7. doi: 10.1093/annonc/mdw005. Epub 2016 Jan 22.

25.

Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1,4,5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263.

Greenberg EF, McColl KS, Zhong F, Wildey G, Dowlati A, Distelhorst CW.

Cell Death Dis. 2015 Dec 31;6:e2034. doi: 10.1038/cddis.2015.355.

26.

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.

Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, Desai R, Escarpe PA, Hampl J, Laysang A, Liu D, Lopez-Molina J, Milton M, Park A, Pysz MA, Shao H, Slingerland B, Torgov M, Williams SA, Foord O, Howard P, Jassem J, Badzio A, Czapiewski P, Harpole DH, Dowlati A, Massion PP, Travis WD, Pietanza MC, Poirier JT, Rudin CM, Stull RA, Dylla SJ.

Sci Transl Med. 2015 Aug 26;7(302):302ra136. doi: 10.1126/scitranslmed.aac9459.

27.

Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.

Halmos B, Pennell NA, Fu P, Saad S, Gadgeel S, Otterson GA, Mekhail T, Snell M, Kuebler JP, Sharma N, Dowlati A.

Oncologist. 2015 Nov;20(11):1298-303. doi: 10.1634/theoncologist.2015-0136. Epub 2015 Aug 25.

28.

Beyond adenocarcinoma: current treatments and future directions for squamous, small cell, and rare lung cancer histologies.

Gerber DE, Paik PK, Dowlati A.

Am Soc Clin Oncol Educ Book. 2015:147-62. doi: 10.14694/EdBook_AM.2015.35.147. Review.

29.

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS.

Lancet Oncol. 2015 Mar;16(3):257-65. doi: 10.1016/S1470-2045(15)70054-9. Epub 2015 Feb 20.

30.

CD30 is a potential therapeutic target in malignant mesothelioma.

Dabir S, Kresak A, Yang M, Fu P, Wildey G, Dowlati A.

Mol Cancer Ther. 2015 Mar;14(3):740-6. doi: 10.1158/1535-7163.MCT-14-0972. Epub 2015 Jan 14.

31.

PIAS3 expression in squamous cell lung cancer is low and predicts overall survival.

Abbas R, McColl KS, Kresak A, Yang M, Chen Y, Fu P, Wildey G, Dowlati A.

Cancer Med. 2015 Mar;4(3):325-32. doi: 10.1002/cam4.372. Epub 2015 Jan 9.

32.

Pharmacogenomic approach to identify drug sensitivity in small-cell lung cancer.

Wildey G, Chen Y, Lent I, Stetson L, Pink J, Barnholtz-Sloan JS, Dowlati A.

PLoS One. 2014 Sep 8;9(9):e106784. doi: 10.1371/journal.pone.0106784. eCollection 2014.

33.

Low PIAS3 expression in malignant mesothelioma is associated with increased STAT3 activation and poor patient survival.

Dabir S, Kluge A, Kresak A, Yang M, Fu P, Groner B, Wildey G, Dowlati A.

Clin Cancer Res. 2014 Oct 1;20(19):5124-32. doi: 10.1158/1078-0432.CCR-14-1233. Epub 2014 Aug 14.

34.

RET mutation and expression in small-cell lung cancer.

Dabir S, Babakoohi S, Kluge A, Morrow JJ, Kresak A, Yang M, MacPherson D, Wildey G, Dowlati A.

J Thorac Oncol. 2014 Sep;9(9):1316-23. doi: 10.1097/JTO.0000000000000234.

35.

Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancer.

Dermawan JK, Gurova K, Pink J, Dowlati A, De S, Narla G, Sharma N, Stark GR.

Mol Cancer Ther. 2014 Sep;13(9):2203-14. doi: 10.1158/1535-7163.MCT-14-0013. Epub 2014 Jul 15.

36.

Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers.

Mittal K, Koon H, Elson P, Triozzi P, Dowlati A, Chen H, Borden EC, Rini BI.

Cancer Biol Ther. 2014 Aug;15(8):975-81. doi: 10.4161/cbt.29187. Epub 2014 May 19.

37.

Defining subgroups of small-cell lung cancer.

Dowlati A, Wildey G.

J Thorac Oncol. 2014 Jun;9(6):750-1. doi: 10.1097/JTO.0000000000000176. No abstract available.

38.

Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.

Tan AR, Dowlati A, Stein MN, Jones SF, Infante JR, Bendell J, Kane MP, Levinson KT, Suttle AB, Burris HA 3rd.

Br J Cancer. 2014 May 27;110(11):2647-54. doi: 10.1038/bjc.2014.233. Epub 2014 May 6.

39.

Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.

Schwandt A, von Gruenigen VE, Wenham RM, Frasure H, Eaton S, Fusco N, Fu P, Wright JJ, Dowlati A, Waggoner S.

Invest New Drugs. 2014 Aug;32(4):729-38. doi: 10.1007/s10637-014-0078-5. Epub 2014 Mar 12.

PMID:
24619298
40.

Clinical trial design in small cell lung cancer: surrogate end points and statistical evolution.

Nickolich M, Babakoohi S, Fu P, Dowlati A.

Clin Lung Cancer. 2014 May;15(3):207-12. doi: 10.1016/j.cllc.2013.12.001. Epub 2013 Dec 27.

PMID:
24485231
41.

A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061.

Rudek MA, Moore PC, Mitsuyasu RT, Dezube BJ, Aboulafia D, Gerecitano J, Sullivan R, Cianfrocca ME, Henry DH, Ratner L, Haigentz M Jr, Dowlati A, Little RF, Ivy SP, Deeken JF.

Cancer. 2014 Apr 15;120(8):1194-202. doi: 10.1002/cncr.28554. Epub 2014 Jan 28.

42.

Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer.

Sharma N, Pennell N, Nickolich M, Halmos B, Ma P, Mekhail T, Fu P, Dowlati A.

Invest New Drugs. 2014 Apr;32(2):362-8. doi: 10.1007/s10637-013-0061-6. Epub 2014 Jan 15.

PMID:
24420556
43.

The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations.

Denicoff AM, McCaskill-Stevens W, Grubbs SS, Bruinooge SS, Comis RL, Devine P, Dilts DM, Duff ME, Ford JG, Joffe S, Schapira L, Weinfurt KP, Michaels M, Raghavan D, Richmond ES, Zon R, Albrecht TL, Bookman MA, Dowlati A, Enos RA, Fouad MN, Good M, Hicks WJ, Loehrer PJ Sr, Lyss AP, Wolff SN, Wujcik DM, Meropol NJ.

J Oncol Pract. 2013 Nov;9(6):267-76. doi: 10.1200/JOP.2013.001119. Epub 2013 Oct 15.

44.

Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas.

Chee CE, Krishnamurthi S, Nock CJ, Meropol NJ, Gibbons J, Fu P, Bokar J, Teston L, O'Brien T, Gudena V, Reese A, Bergman M, Saltzman J, Wright JJ, Dowlati A, Brell J.

Oncologist. 2013;18(10):1091-2. doi: 10.1634/theoncologist.2013-0255. Epub 2013 Sep 26.

45.

PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 status.

Dabir S, Kluge A, McColl K, Liu Y, Lam M, Halmos B, Wildey G, Dowlati A.

Int J Cancer. 2014 Mar 1;134(5):1045-54. doi: 10.1002/ijc.28448. Epub 2013 Sep 23.

46.

Synthesis and anticancer mechanism investigation of dual Hsp27 and tubulin inhibitors.

Zhong B, Chennamaneni S, Lama R, Yi X, Geldenhuys WJ, Pink JJ, Dowlati A, Xu Y, Zhou A, Su B.

J Med Chem. 2013 Jul 11;56(13):5306-20. doi: 10.1021/jm4004736. Epub 2013 Jun 28.

47.

Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.

Shibata SI, Chung V, Synold TW, Longmate JA, Suttle AB, Ottesen LH, Lenz HJ, Kummar S, Harvey RD, Hamilton AL, O'Neil BH, Sarantopoulos J, LoRusso P, Rudek MA, Dowlati A, Mulkerin DL, Belani CP, Gandhi L, Lau SC, Ivy SP, Newman EM.

Clin Cancer Res. 2013 Jul 1;19(13):3631-9. doi: 10.1158/1078-0432.CCR-12-3214. Epub 2013 May 7.

48.

Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers.

Kunos CA, Radivoyevitch T, Waggoner S, Debernardo R, Zanotti K, Resnick K, Fusco N, Adams R, Redline R, Faulhaber P, Dowlati A.

Gynecol Oncol. 2013 Jul;130(1):75-80. doi: 10.1016/j.ygyno.2013.04.019. Epub 2013 Apr 18.

49.

A Phase I study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer.

Halmos B, Jia Y, Bokar JA, Fu P, Adelstein DJ, Juergens R, Rodal MB, Dowlati A.

Invest New Drugs. 2013 Oct;31(5):1244-50. doi: 10.1007/s10637-013-9945-8. Epub 2013 Apr 4.

PMID:
23553066
50.

Phase I trials of targeted anticancer drugs: a need to refocus.

Borden EC, Dowlati A.

Nat Rev Drug Discov. 2012 Dec;11(12):889-90. doi: 10.1038/nrd3909.

PMID:
23197020

Supplemental Content

Loading ...
Support Center